The main clinical significance of anti-cyclic citrullinated peptide antibody is a highly specific indicator for the early diagnosis of rheumatoid arthritis, and positivity is mostly indicative of the possibility of the presence of rheumatoid arthritis. Anti-cyclic citrullinated peptide antibody is an autoantibody with synthetic cyclized citrullinated peptide as antigen, which has high sensitivity and specificity for rheumatoid arthritis, and is a highly specific indicator for early diagnosis of rheumatoid arthritis. Anti-cyclic citrullinated peptide antibody is normally negative, and when it suggests positivity, it suggests a high likelihood of rheumatoid arthritis. Anti-cyclic citrullinated peptide antibody is a highly specific indicator for the diagnosis of early rheumatoid arthritis. If the test is negative, rheumatoid arthritis is less likely, but not completely excluded. If the test is positive, the likelihood of rheumatoid arthritis is high. Patients with positive anti-cyclic citrullinated peptide antibodies are more likely to have joint damage than those with negative anti-cyclic citrullinated peptide antibodies. Rheumatoid arthritis is a systemic autoimmune disease, which is characterized by swelling and pain in several joints. If the disease is not diagnosed and treated in time, it is prone to erosive changes in cartilage and bone, which can eventually lead to different degrees of disability, so patients need to be detected, diagnosed and treated as early as possible. When the test result of anti-cyclic citrullinated peptide antibody is positive, it is recommended that the patient should consult a doctor in time and standardize the diagnosis and treatment under the guidance of the doctor.